ISIN | LU2226244361 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Galileo – Biotech Innovation Fund BC USD |
Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
Fund Provider | IPConcept (Luxemburg) S.A. |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) | Bellecapital AG |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
Peculiarities |
Current Price * | 37.57 USD | 02.06.2025 |
---|---|---|
Previous Price * | 38.39 USD | 30.05.2025 |
52 Week High * | 65.08 USD | 17.07.2024 |
52 Week Low * | 33.21 USD | 09.04.2025 |
NAV * | 37.57 USD | 02.06.2025 |
Issue Price * | 37.57 USD | 02.06.2025 |
Redemption Price * | 37.57 USD | 02.06.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 24,951,021 | |
Unit/Share Assets *** | 24,039,913 | |
Trading Information SIX |
YTD Performance | -20.01% |
30.12.2024 - 02.06.2025
30.12.2024 02.06.2025 |
---|---|---|
YTD Performance (in CHF) | -27.24% |
30.12.2024 - 02.06.2025
30.12.2024 02.06.2025 |
1 month | -6.64% |
02.05.2025 - 02.06.2025
02.05.2025 02.06.2025 |
3 months | -13.09% |
03.03.2025 - 02.06.2025
03.03.2025 02.06.2025 |
6 months | -31.85% |
02.12.2024 - 02.06.2025
02.12.2024 02.06.2025 |
1 year | -36.94% |
03.06.2024 - 02.06.2025
03.06.2024 02.06.2025 |
2 years | -40.91% |
02.06.2023 - 02.06.2025
02.06.2023 02.06.2025 |
3 years | -41.53% |
02.06.2022 - 02.06.2025
02.06.2022 02.06.2025 |
5 years | -74.95% |
31.03.2021 - 02.06.2025
31.03.2021 02.06.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Krystal Biotech Inc | 9.28% | |
---|---|---|
Arcellx Inc | 8.53% | |
Poseida Therapeutics Inc Ordinary Shares | 7.94% | |
Alnylam Pharmaceuticals Inc | 4.07% | |
Stoke Therapeutics Inc | 3.30% | |
Sarepta Therapeutics Inc | 3.13% | |
Iovance Biotherapeutics Inc | 2.90% | |
Q32 Bio Inc | 2.41% | |
Rocket Pharmaceuticals Inc | 2.27% | |
CRISPR Therapeutics AG | 2.20% | |
Last data update | 30.11.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | |
Ongoing Charges *** | 0.44% |
SRRI ***
|
|
SRRI date *** | 31.05.2025 |